{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T20:46:04Z","timestamp":1759178764943},"reference-count":0,"publisher":"PAGEPress Publications","issue":"3","license":[{"start":{"date-parts":[[2019,10,24]],"date-time":"2019-10-24T00:00:00Z","timestamp":1571875200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Reumatismo"],"abstract":"<jats:p>Treat-to-target (T2T) for gout has been established recently to improve its management, which has been reported to be sub-optimal with significant gaps between the goals of treatment and day-to-day clinical practice. T2T recommended a goal of serum urate (SUA) target of &lt;360 \u03bcmoI\/L in all patients with gout and &lt;300 \u03bcmoI\/L in patients with tophaceous or severe gout. T2T strategy was applied in the management of gout patients in two Rheumatology clinics from 1 January 2016 onwards. We performed a clinical audit to assess T2T of SUA in gout patients and to identify causes for failure to achieve target SUA among them. There were a total of 304 patients for our analysis. They were of multi-ethnic origin with male predominance (88.8%). They had a mean age of 57.7+13.7 years and mean disease duration of 10.1+8.7 years. The most common comorbidities were hypertension (76.2%), dyslipidemia (52.5%) and diabetes mellitus (DM) (27.4%). Our patients\u2019 body mass indexes showed that 47.7% were obese while 34.2% were overweight. Up to 62.4% of our patients had tophi and 42.6% had joint deformities. Only 34.9% of patients achieved target SUA. Nonadherence (52.3%) was the main reason identified for failure to achieve target SUA. The independent predictors for failure to achieve target SUA were nonadherence (HR=7.84, p=0.000) and presence of tophi (HR=1.95, p=0.001).<\/jats:p>","DOI":"10.4081\/reumatismo.2019.1225","type":"journal-article","created":{"date-parts":[[2019,10,24]],"date-time":"2019-10-24T15:16:30Z","timestamp":1571930190000},"page":"154-159","source":"Crossref","is-referenced-by-count":6,"title":["Treat-to-target (T2T) of serum urate (SUA) in gout: a clinical audit in real-world gout patients"],"prefix":"10.4081","volume":"71","author":[{"given":"C.L.","family":"Teh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.K.","family":"Cheong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.A.","family":"Wan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.R.","family":"Ling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2549","published-online":{"date-parts":[[2019,10,24]]},"container-title":["Reumatismo"],"original-title":[],"link":[{"URL":"https:\/\/reumatismo.org\/index.php\/reuma\/article\/download\/1225\/849","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/reumatismo.org\/index.php\/reuma\/article\/download\/1225\/849","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,16]],"date-time":"2020-04-16T00:18:21Z","timestamp":1586996301000},"score":1,"resource":{"primary":{"URL":"https:\/\/reumatismo.org\/index.php\/reuma\/article\/view\/1225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,24]]},"references-count":0,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,10,24]]}},"URL":"https:\/\/doi.org\/10.4081\/reumatismo.2019.1225","relation":{},"ISSN":["2240-2683","0048-7449"],"issn-type":[{"value":"2240-2683","type":"electronic"},{"value":"0048-7449","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10,24]]}}}